Stock Analiz

Ionis Pharmaceuticals Inc. (IONS) financials: revenue, earnings and cash flow

Fiscal 2016–2025 + TTM · from SEC filings · data as of November 13, 2026

Summary

Ionis Pharmaceuticals’s revenue went from $373M in fiscal 2016 to $944M in fiscal 2025, growth of about 10.9% a year.

Net income in fiscal 2025 was -$381M, a net margin of -40.4%; the best year in this period was 2019 with $278M.

Over the twelve months to September 30, 2026, revenue was $960M and net income -$547M.

Free cash flow was -$320M in fiscal 2025 and positive in 5 of the 10 years shown.

The diluted share count rose 32% over the period (dilution).

Revenue, profit and cash flow by year

Revenue
2016: $373M162017: $508M172018: $600M182019: $1.1B192020: $729M202021: $810M212022: $587M222023: $788M232024: $705M242025: $944M25$944M
Net income
2016: -$60M162017: $346000172018: $274M182019: $278M192020: -$444M202021: -$29M212022: -$270M222023: -$366M232024: -$454M242025: -$381M25-$381M
Free cash flow
2016: -$119M162017: $139M172018: $589M182019: $315M192020: $772000202021: $19M212022: -$290M222023: -$331M232024: -$546M242025: -$320M25-$320M
EPS (diluted)
2016: $-0.50162017: $0.15172018: $2.07182019: $1.90192020: $-3.18202021: $-0.20212022: $-1.90222023: $-2.56232024: $-3.04242025: $-2.3825$-2.38

Income statement

Fiscal yearTTM2025202420232022202120202019201820172016
Revenue$960M$944M$705M$788M$587M$810M$729M$1.1B$600M$508M$373M
Gross profit$943M$928M$694M$779M$573M$800M$717M$1.1B$598M$508M$373M
Operating income-$565M-$382M-$475M-$354M-$410M-$30M-$172M$366M-$61M$31M-$20M
Net income-$547M-$381M-$454M-$366M-$270M-$29M-$444M$278M$274M$346000-$60M
EPS (diluted)$-3.32$-2.38$-3.04$-2.56$-1.90$-0.20$-3.18$1.90$2.07$0.15$-0.50
R&D—$916M$902M$900M—$638M$531M$462M$412M$372M$340M
Revenue growth—+33.8%−10.5%+34.1%−27.5%+11.1%−35.0%+87.2%+18.1%+36.2%+31.4%

Cash flow

Fiscal yearTTM2025202420232022202120202019201820172016
Operating cash flow-$544M-$269M-$501M-$308M-$274M$31M$36M$346M$603M$174M-$112M
Capital spending-$72M-$51M-$45M-$24M-$16M-$12M-$35M-$31M-$14M-$35M-$7M
Free cash flow-$616M-$320M-$546M-$331M-$290M$19M$772000$315M$589M$139M-$119M
Dividends paid—$0$0$0$0$0$0$0$0$0$0
Buybacks————$0$0$91M$34M$0$0—
Stock-based pay$176M$134M$130M$106M$100M$121M$230M$147M$131M$86M$72M

Balance sheet

Fiscal yearTTM2025202420232022202120202019201820172016
Cash—$2.7B$2.3B$2.3B$2.0B$2.1B$1.9B$2.5B$2.1B$1.0B$665M
Debt—$2.1B$1.4B$1.5B$1.4B$22M$857M$805M$582M$535M$502M
Equity—$489M$588M$387M$573M$772M$743M$1.5B$1.0B$281M$100M
Total assets—$3.5B$3.0B$3.0B$2.5B$2.6B$2.4B$3.2B$2.7B$1.3B$912M
Shares (diluted)166M160M150M143M142M141M140M153M134M126M121M

Margins and returns

Fiscal yearTTM2025202420232022202120202019201820172016
Gross margin98.2%98.3%98.4%98.8%97.6%98.7%98.4%99.6%99.7%100.0%100.0%
Operating margin-58.8%-40.5%-67.4%-44.9%-69.8%-3.7%-23.6%32.6%-10.2%6.1%-5.4%
Net margin-56.9%-40.4%-64.4%-46.5%-45.9%-3.5%-60.9%24.8%45.6%0.1%-16.2%
FCF margin-64.2%-33.9%-77.5%-42.1%-49.4%2.3%0.1%28.0%98.3%27.5%-32.0%
ROIC—-11.7%-23.3%-14.9%-16.6%-3.7%-8.5%13.6%-3.0%2.5%-2.6%
ROE—-78.0%-77.1%-94.7%-47.1%-3.7%-59.8%18.9%26.1%0.1%-60.7%

Frequently asked questions

What is Ionis Pharmaceuticals’s annual revenue?

$944M in fiscal 2025 and $960M over the twelve months to September 30, 2026.

How much profit does Ionis Pharmaceuticals make?

Net income was -$381M in fiscal 2025 (net margin -40.4%).

Is Ionis Pharmaceuticals’s revenue growing?

Yes: revenue rose 33.8% in fiscal 2025 compared with the year before.

From the company’s 10-K and 10-Q filings with the SEC; per-share figures adjusted for stock splits. Rebuilt daily. Not investment advice.